A genome-wide comprehensively analyses of long noncoding RNA profiling and metastasis associated lncRNAs in renal cell carcinoma
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1476 views | HTML 2268 views | ?
Xue Xu1,*, Yongcan Xu2,*, Chuanqin Shi1, Baoyu Wang1, Xiang Yu3, Yanfen Zou4 and Tao Hu1
1Department of Immunology, Binzhou Medical College, Yantai 264003, China
2Department of General Surgery, Huzhou Central Hospital, Huzhou 313000, China
3Department of General Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai 264000, China
4Department of Obstetrics and Gynecology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai 264000, China
*These authors have contributed equally to this work
Tao Hu, email: [email protected]
Yanfen Zou, email: [email protected]
Xiang Yu, email: [email protected]
Keywords: renal cell carcinoma, lncRNAs profiling, metastasis, prognosis, marker
Received: July 04, 2017 Accepted: August 04, 2017 Published: September 23, 2017
Recently, a growing number of studies have indicated that long noncoding RNAs (lncRNAs) are emerging as new critical regulators of tumorigenesis and prognostic markers in multiple cancers. However, the expression pattern of lncRNAs and their contributions in renal cell carcinoma (RCC) remains poorly understood. In this study, we performed a genome-wide comprehensively analysis of lncRNAs profiling and clinical relevance to provide valuable lncRNA candidates for the further study in RCC. RCC and non-tumor tissues RNA sequencing data, and microarray data were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), then, these data were annotated and analyzed to find dysregulated lncRNAs in RCC. We identified that hundreds of lncRNAs were differentially expressed in RCC tissues compared with normal tissues, and genomic variation analyses revealed that copy number amplification or deletion happened in some of these lncRNAs genome loci. Moreover, lots of lncRNAs expression levels are significantly associated RCC patients overall survival time, such as PVT1 and DUXAP8. Finally, we identified some novel metastasis associated lncRNAs in RCC (such as DUXAP8) by analyzing lncRNAs profiling in the RCC tissues from patients with metastasis compared with the primary RCC tissues without metastasis; knockdown of DUXAP8 could impair RCC cells invasive ability in vitro. Overall, our findings illuminate a lot of lncRNAs are aberrantly expressed in RCC that may offer useful resource for identification novel prognostic markers in this disease.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.